1. Hepatoblastoma: Analysis of treatment outcome from a tertiary care center
- Author
-
Tenali Gnana Sagar, Ramakrishnan Ayloor Seshadri, Sanju Cyriac, and Arun Warrier
- Subjects
neoadjuvant treatment ,Hepatoblastoma ,medicine.medical_specialty ,medicine.medical_treatment ,Treatment outcome ,Population ,lcsh:Surgery ,Disease ,Tertiary care ,medicine ,Chemotherapy ,hepatic resections ,multimodality treatment ,education ,Cisplatin ,education.field_of_study ,business.industry ,Multimodality Treatment ,lcsh:RJ1-570 ,lcsh:Pediatrics ,lcsh:RD1-811 ,hepatoblastoma ,medicine.disease ,Surgery ,Pediatrics, Perinatology and Child Health ,Original Article ,business ,medicine.drug - Abstract
Aim : This study was designed to retrospectively review our experience with the multimodality management of hepatoblastomas (HB). Materials and Methods: Thirteen patients were treated for HB between 2000 and 2007. The clinical presentations, chemotherapy tolerance and response, surgical procedure undertaken, and complications were analysed. Results: Median age of the population was 12 months (3-60 months), with a male-to-female ratio of 3.3:1. Nine patients were treated with neoadjuvant chemotherapy incorporating cisplatin and adriamycin. Primary surgery was done in four patients. Extent of hepatic resection in the operated patients varied. Mixed type was the predominant histopathological diagnosis. Adjuvant chemotherapy was well tolerated with no morbidity or mortality. Five-year event-free survival (EFS) and overall survival (OS) of all the 13 patients is 76.9%. All the nine patients who could complete multimodality treatment are alive with no evidence of disease or complications with median follow-up of 63 months (46-122 months). Conclusions: Treatment of HB with multidisciplinary approach was well tolerated. OS and EFS of patients were comparable with published studies.
- Published
- 2011